UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, 15224, United States
Location status: Recruiting
Location contact
Daniel Pieratt, MPA
CONTACT
Morgan L Paul, BSN
CONTACT
Rakesh Sindhi, MD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT03273049
This project will primarily evaluate the developmental/genetic basis of biliary atresia, the most common cause of liver failure at birth, and which accounts of half of all liver transplants performed worldwide in children.
Interested in participating?
Request InfoAll sexes
Observational
Pittsburgh, Pennsylvania, 15224, United States
Location status: Recruiting
Daniel Pieratt, MPA
CONTACT
Morgan L Paul, BSN
CONTACT
Rakesh Sindhi, MD
PRINCIPAL_INVESTIGATOR
Characterized by failure to drain bile from the liver due to atretic extrahepatic bile ducts, BA is corrected in less than half of all affected children with surgical reconstruction. The remainder progress to cirrhosis and require liver transplantation. Because bile duct loss can be accompanied by other birth defects such as laterality defects of the gut and cardiovascular systems, the disease has been categorized into the more common 'isolated' variety presumably due to a perinatal viral cholangitis, and the 'syndromic' variety, due to genetic factors. Mechanistic differences implied by this categorization have not been demonstrated conclusively. In contrast, three susceptibility genes identified in predominantly 'isolated" BA cases, and the presence of abnormal cilia which are known to predispose to laterality defects, in both isolated and syndromic forms of BA suggest that in addition to environmental influences, genetic susceptibility is important in both forms of BA. This view is reinforced by our preliminary work which shows that knockdown of a novel BA susceptibility gene causes both biliary dysgenesis and laterality defects in animal models. This finding also suggests that common birth defects affecting the liver and other organs may originate from defects in the same genes. The project will combine candidate gene identification and replication with human DNA samples from 1100 BA subjects and their biological parents or siblings, if available, with validation using corresponding human BA liver tissue and zebrafish knockdown models.
The project outcome will consist of pathways comprising multiple susceptibility genes involved in morphogenesis of the liver and other organs, which explain the complex phenotype of BA. The project will use the experimental and bioinformatics capabilities of the Universities of Pittsburgh and California (at San Diego) to analyze data and study human samples from the participating centers. Four of the world's largest pediatric liver transplant centers, the Children's Hospitals of Pittsburgh (CHP), King's College Hospital (KCH), London, UK, Birmingham Children's Hospital, UK (BCH), and the Hospital Sirio Libanes (HSL), Sao Paulo, Brazil will enroll biliary atresia subjects and their biological parents and/or siblings, if available.
Information developed in this project will be the basis for designing novel management strategies to reduce the societal impact of this rare childhood disease.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: up to two years
Main project outcome will consist of pathways comprising multiple susceptibility genes involved in morphogenesis of the liver and other organs, which explain the complex phenotype of BA.
Time frame: upwards of four years to achieve this outcome measure
determine whether candidate genes and related pathways which predispose to BA, also predispose to laterality defects affecting the liver and other organs.
Contact information is provided by the study sponsor or research team.
Daniel Pieratt, MPA
CONTACT
Morgan L Paul, BSN
CONTACT
University of Pittsburgh
Other
Coordinating Center- Mapping Disease Pathways for Biliary Atresia
Acronym: BA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04272515
Bile Duct Diseases, Biliary Atresia
Paris, De, France
View Trial DetailsNCT07697872
Bile Duct Diseases, Biliary Atresia
Birmingham, United Kingdom
View Trial DetailsNCT00345553
Bile Duct Diseases, Biliary Atresia
Los Angeles, California, United States
View Trial DetailsNCT00061828
Bile Duct Diseases, Biliary Atresia
Los Angeles, California, United States
View Trial Details